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Abstract: AMP-activated protein kinase (AMPK) is a pivotal regulator of metabolism at the 
cellular and organismal levels. AMPK also suppresses inflammation. We found that pharmacological 
activation of AMPK rapidly inhibited the Janus kinase (JAK)–signal transducer and activator of 
transcription (STAT) pathway in various cells. In vitro kinase assays revealed that AMPK directly 
phosphorylated two residues (Ser515 and Ser518) within the SH2 domain of JAK1. Activation of 
AMPK enhanced the interaction between JAK1 and 14-3-3 proteins in cultured vascular endothelial 
cells and fibroblasts, an effect which required the presence of Ser515 and Ser518 and was abolished 
in cells lacking AMPK catalytic subunits. Mutation of Ser515 and Ser518 abolished AMPK-
mediated inhibition of JAK-STAT signaling stimulated either by the sIL-6Rα/IL-6 complex or 
by expression of a constitutively active V658F-mutant JAK1 in human fibrosarcoma cells. 
Clinically used AMPK activators metformin and salicylate enhanced the inhibitory 
phosphorylation of endogenous JAK1 and inhibited STAT3 phosphorylation in primary vascular 
endothelial cells. Therefore our findings reveal a mechanism by which JAK1 function and 
inflammatory signaling may be suppressed in response to metabolic stress and provide a 
mechanistic rationale for the investigation of AMPK activators in a range of diseases associated 
with enhanced activation of the JAK-STAT pathway. 
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Introduction 
The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway 
mediates signaling by a range of cytokines that can stimulate or inhibit survival, proliferation and 
differentiation responses in diverse cell types. JAKs comprise a family of four cytoplasmic 
tyrosine kinases (JAK1, JAK2, JAK3, and Tyk2) that function as essential signaling components 
immediately downstream of receptors for many hematopoietic cytokines, such as granulocyte-
macrophage colony-stimulating factor, erythropoietin, leptin, interferons (IFNs) and interleukins 
such as IL-6 (1)(2). The IL-6 receptor comprises two distinct subunits, an IL-6-binding protein 
(IL-6Rα) and a 130 kD signal-transducing subunit (gp130) which is shared by all IL-6-family 
cytokines (2). The gene encoding gp130 subunit is ubiquitously expressed, whereas that 
encoding IL-6Rα is restricted to hepatocytes, monocytes, neutrophils, and some B and T cell 
subsets. However, IL-6 can also bind a soluble form of the receptor (sIL-6Rα) generated either 
by limited proteolytic cleavage of membrane-bound IL-6Rα or alternate splicing of IL-6Rα 
primary transcripts. The resulting sIL-6Rα/IL-6 “trans-signaling” complexes can then associate 
with gp130 on cells that do not express the membrane-bound IL-6R, thereby widening the 
spectrum of IL-6-responsive cells (3). 
IL-6 binding to the receptor complex results in the activation of gp130-bound JAKs. The 
activated JAKs are then able to phosphorylate specific Tyr residues within the receptor’s 
cytoplasmic domain, which serve as docking sites for SH2 domain-containing proteins. The 
major intracellular mediators are the STAT proteins. IL-6 is capable of activating STAT1 and 
STAT3, although STAT3 activation has been observed to a greater extent than STAT1. 
Activation of STATs require their recruitment to specific JAK-phosphorylated Tyr residues on 
gp130 via their SH2 domain followed by JAK-mediated phosphorylation of a Tyr residue in the 
transactivation domain (Tyr705 on STAT3, Tyr701 on STAT1). Tyr-phosphorylated STATs then 
form dimers which can translocate to the nucleus to activate target gene transcription. IL-6 can 
also activate extracellular signal-regulated kinase 1 (ERK1) and ERK2 and phosphatidylinositol 
3-kinase pathways following recruitment of the Tyr phosphatase SHP2 to JAK-phosphorylated 
gp130 (2)(4). 
AMP-activated protein kinase (AMPK) is the highly conserved downstream component of a 
Ser/Thr protein kinase cascade involved in the regulation of metabolism. It was initially 
characterised as a Ser/Thr protein kinase that is allosterically activated by increases in 
intracellular AMP concentration resulting from a decline in intracellular ATP that occurs after 
nutrient deprivation or hypoxia (5)(6). AMPK is a heterotrimeric complex comprised of a 
catalytic α subunit and regulatory β and γ subunits. In mammals, isoforms of each subunit (α1, 
α2, β1, β2, γ1, γ2, γ3) are encoded by seven genes. The β subunits are each N-terminally 
myristoylated, contain carbohydrate-binding domains and interact with both the α and γ subunits, 
whereas the γ subunits contain the AMP/ADP binding sites responsible for sensing cellular 
energy status [reviewed in (5)]. In addition to the allosteric activation of AMPK by adenine 
nucleotides, AMP or ADP binding to the regulatory γ subunit of AMPK promotes 
phosphorylation of the catalytic α subunit at Thr172, which is required for AMPK activity. 
Binding of AMP and ADP also inhibits dephosphorylation of AMPK, maintaining Thr172 
phosphorylation by the upstream AMPK Thr172 kinase, liver kinase B1 (LKB1) (5)(6). In the 
absence of changes in adenine nucleotide ratios, AMPK can be activated by increases in 
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intracellular Ca2+ concentrations in cells expressing Ca2+/calmodulin-dependent protein kinase 
kinase β (CaMKKβ) (5)(6). 
The most studied aspect of AMPK function is its role in maintaining cellular energy stores and 
regulating whole body energy balance. An important aspect of this role is the direct 
phosphorylation of metabolic enzymes such as acetyl coA carboxylase (ACC) 1 and 2, which 
catalyze the carboxylation of acetyl coA to malonyl-CoA, a key substrate for fatty acid 
biosynthesis that also inhibits fatty acid transport into mitochondria (7). AMPK-mediated 
phosphorylation of ACC1 on Ser79 inhibits its activity thereby suppressing fatty acid synthesis 
and enhancing β-oxidation (8). An increasing body of evidence has revealed that AMPK is also 
an important regulator of inflammatory responses. For example, AMPK-dependent inhibition of 
tumor necrosis factor α (TNFα)-, lipopolysaccharide (LPS)- and interleukin-1β (IL-1β)-
stimulated leukocyte recruitment to vascular endothelial cells in culture has been observed in 
multiple studies, and is associated with reduced induction of adhesion molecules (such as 
VCAM-1 and E-selectin) and chemokines (such as CCL2 and CCL3) (9)(10). Studies using 
PRKAA1-/- and PRKAA2-/- mice, which lack AMPKα1 and AMPKα2 catalytic subunits 
respectively, suggest that both isoforms can contribute to inhibition of post-ischemic leukocyte 
adhesion to blood vessels by the AMPK activator 5’-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR) (11). Consistent with a role for AMPK in suppressing inflammation in 
vivo, aortae from AMPKα1-/- mice have been shown to display enhanced angiotensin II-
stimulated VCAM-1 expression (12). Activation of AMPK with AICAR is also associated with 
reduced infiltration of inflammatory cells in rodent models of acute and chronic colitis (13), lung 
injury (14) and autoimmune encephalomyelitis (15). Furthermore, increased infiltration and 
activation of macrophages have been observed in adipose tissue from wild type mice 
transplanted with bone marrow from AMPKβ1-/- mice (16). Therefore, taken as a whole, it has 
become clear that AMPK can limit inflammatory cell infiltration and activation in multiple 
settings.  
Whereas AMPK’s ability to maintain fatty acid oxidation in macrophages has been proposed as 
an important mechanism by which it limits inflammation in macrophages (16), several 
mechanisms have also been identified though which AMPK can directly inhibit pro-
inflammatory signaling pathways. However, while several potential mechanisms have been 
proposed to explain AMPK-mediated inhibition of the NF-κB pathway in response to stimuli 
such as TNFα, LPS and IL-1 (9)(17), relatively few studies have examined how the JAK-STAT 
pathway is controlled by AMPK. This is a particularly important issue to address given the 
pathological roles of enhanced JAK-STAT signaling in multiple chronic inflammatory 
conditions such as atherosclerosis, colitis and rheumatoid arthritis, as well as several cancers and 
hematological disorders driven by mutational activation of JAK isoforms (1)(18)(19)(20). 
In this study, we found that AMPK could rapidly and profoundly inhibit activation of the JAK-
STAT pathway in response to multiple stimuli. In addition, we show that this occurs through a 
previously unappreciated mechanism involving direct AMPK-mediated phosphorylation of 
JAK1 within its regulatory SH2 domain. Our data therefore reveal how metabolic stress can 
rapidly inhibit signaling from JAK1, and provide a molecular basis for potential repurposing of 
AMPK activators for a range of diseases associated with enhanced activation of the JAK-STAT 
pathway. 
Results 
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AMPK rapidly inhibits IL-6 signaling and function 
AMPK plays a largely protective role in vascular endothelial cells (ECs) via both nitric oxide 
(NO)-dependent and –independent mechanisms (21)(22). Incubation of human umbilical vein 
ECs (HUVECs) with sIL-6Rα/IL-6 trans-signaling complexes for 30 min significantly increased 
the phosphorylation of STAT3 on Tyr705 (Fig. 1A), an effect that was significantly inhibited in 
HUVECs that had been pre-incubated with distinct stimuli that each activate AMPK as 
determined by assessing ACC1 phosphorylation on Ser79 (8): AICAR, which is phosphorylated 
intracellularly to the AMP mimetic ZMP (23); A769662, which binds and activates β1-
containing AMPK complexes via an AMP/ADP-independent mechanism (24); and a 
combination of clinically utilized AMPK activators metformin and salicylate, which 
synergistically activate AMPK by increasing intracellular AMP concentration and directly 
binding β1-subunits, respectively (25)(26)(27). Under these conditions, AMPK activation on its 
own had no detectable effect on the phosphorylation of STAT3. Targeted short inhibitory RNA 
(siRNA)-mediated knockdown of AMPKα1 catalytic subunits reduced the inhibitory effects of 
both A769662 (Fig. 1B) and AICAR (fig. S1), indicating that these effects were mediated via 
AMPK activation. In addition, compared with controls, adenovirus (AV)-mediated expression of 
a catalytically inactive dominant negative (DN) AMPKα1 subunit, in which Asp157 located 
within subdomain VII of the catalytic domain is mutated to Ala (28), was sufficient to block 
A769662-mediated inhibition of STAT3 phosphorylation in HUVECs (fig. S1). Together, these 
data demonstrated that activation of AMPK by multiple stimuli triggered a rapid and significant 
reduction in the ability of sIL-6Rα/IL-6 to stimulate STAT3 phosphorylation on Tyr705. 
To assess the functional consequences of AMPK-mediated inhibition of IL-6 signaling, we 
initially examined the effect of A769662 on IL-6-mediated induction of STAT3 target genes 
suppressor of cytokine signaling 3 (SOCS3) and CCAAT/enhancer binding protein δ (C/EBPδ) 
(29)(30). Similar to the effect on STAT3 phosphorylation, A769662 significantly inhibited sIL-
6Rα/IL-6-stimulated accumulation of SOCS3 and C/EBPδ protein (Fig. 1C) and mRNA (fig. S2) 
abundance. In addition, we took advantage of the well-described ability of IL-6 to induce 
chemokine expression and thereby increase monocyte chemotaxis (20)(31)(32). Conditioned 
media was collected from HUVECs cultured with vehicle, A769662, or sIL-6Rα/IL-6 then 
applied to a trans-well migration assay to assess its capacity to stimulate monocyte migration. 
Because the HUVECs were extensively washed to remove A769662 and sIL-6Rα/IL-6 prior to 
collection of conditioned medium, it is unlikely that there was a substantial residual 
concentration of either that would contribute to migration directly. We found that the migration 
of U937 monocytic cells towards conditioned media from sIL-6Rα/IL-6-stimulated HUVECs 
was significantly greater than that toward conditioned medium from vehicle-treated HUVECs 
(Fig. 1D). Conditioned medium from HUVECs pre-incubated with A769662 for 30 min before 
cytokine stimulation elicited significantly less U937 cell migration compared to conditioned 
media from sIL-6Rα/IL-6-stimulated HUVECs (Fig. 1D). 
AMPK inhibits signaling from multiple cytokine receptor complexes 
To identify the point in the IL-6 signaling pathway at which AMPK was acting, we examined 
signaling downstream of multiple cytokines other cytokine receptors. We found that the 
inhibitory effect of AMPK on sIL-6Rα/IL-6 responses was not restricted to STAT3, given that 
pre-incubation of HUVECs with A769662 also abrogated sIL-6Rα/IL-6-stimulated 
phosphorylation of STAT1 on Tyr701 (Fig. 2A). Whereas IL-6 signals downstream through 
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interaction with either a membrane-bound or soluble IL-Rα and gp130 homodimers, leukemia 
inhibitory factor (LIF) and oncostatin M (OSM) signal through cytokine interaction with 
gp130/LIF receptor (LIFR) and OSM receptor/gp130 heterodimers, respectively (2). Similar to 
sIL-6Rα/IL-6, pre-treatment of HUVECs with A769662 significantly reduced OSM- and LIF-
stimulated phosphorylation of STAT3 and STAT1 (Fig. 2A). In addition, the ability of each 
cytokine to stimulate STAT3 phosphorylation on Ser727, which is critical for full transcriptional 
activation and is mediated by cytokine receptor activation of either the ERK1/2 or 
phosphatidylinositol 3-kinase (PI3K)–mammalian target of rapamycin (mTOR) pathway, was 
similarly reduced by A769662 (Fig. 2A). In support of a post-receptor effect of AMPK, 
A769662 also suppressed STAT3 phosphorylation in response to IFNα, which activates STATs 
through a distinct IFNα/β receptor 1 (IFNAR1)/IFNAR2 complex that lacks gp130 (33) (Fig. 
2B). Together, these results would suggest that AMPK exerts its inhibitory effects on multiple 
cytokine-activated signaling pathways at one or more common loci downstream of both 
IFNAR1/IFNAR2 and gp130-containing cytokine receptor complexes. 
JAK1 is phosphorylated by AMPK in vitro 
The IFNAR1/IFNAR2 complex couples to STATs via JAK1 and Tyk2 (33)(34). We performed 
JAK1, JAK2 and Tyk2 siRNA knockdown experiments in HUVECs which demonstrated that 
JAK1 mediates a substantial proportion of sIL-6Rα/IL-6-stimulated STAT3 activation (fig. S3). 
Thus JAK1 was identified as a potential common AMPK-regulated post-receptor target. As 
AMPK is a Ser/Thr protein kinase, and the inhibitory effect of AMPK activator A769662 
occurred rapidly, we investigated the possibility that AMPK could directly phosphorylate JAK1. 
Peptide arrays of overlapping 25-mer peptides sequentially shifted by five amino acids and 
spanning the full human JAK1 open reading frame (residues 1-1154) were utilized for in vitro 
kinase assays with AMPK purified from rat liver and [γ32P]ATP (35)(36). These experiments 
identified a sequence within the JAK1 SH2 domain (R506YSLHGSDRSFPSLGDLMSHLKKQI) 
as a potential substrate whose phosphorylation on the array was greater than that of the so-called 
“SAMS” peptide typically used as an in vitro substrate for assaying AMPK activity and which is 
based on the primary AMPK phosphorylation site (Ser79) in rat ACC1 (35) (Fig. 3A). To define 
which of the five potential phospho-acceptor sites within the JAK1 peptide were phosphorylated 
in vitro by AMPK, kinase assays were then performed on additional arrays containing the wild-
type peptide sequence and mutant peptides in which each Ser residue was replaced with a non-
phosphorylatable Ala residue either individually or in combination (Fig. 3B). Simultaneous 
replacement of all five Ser residues with Ala abolished AMPK-mediated phosphorylation of the 
peptide. Individual replacement of each Ser residue with Ala either did not alter or enhanced 
AMPK phosphorylation of the resulting peptides. However, simultaneous replacement of Ser515 
and Ser518 with Ala abrogated peptide phosphorylation to the same extent as mutating all five Ser 
residues. In addition, a peptide in which Ser508, Ser512 and Ser524 were all replaced with Ala was 
phosphorylated to the same extent as the wild-type JAK1 sequence (Fig. 3B). Together, these 
observations identified Ser515 and Ser518 in human JAK1 as potential sites of phosphorylation by 
AMPK in vitro. 
Peptide library screening, mutagenesis and molecular modelling studies (37)(38) have all been 
used to identify optimal AMPK substrate motifs. Bioinformatic analysis of JAK1 orthologues 
revealed that phosphorylation sites equivalent to Ser518 in human JAK1 are conserved in multiple 
species (Fig. 3C). Residues at positions +3 and +4 downstream of the phospho-acceptor sites that 
are known to be critical for substrate recognition are also well conserved (Fig. 3C). Ser518 is 
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located at the start of a specific α-helix that is conserved amongst all JAK isoforms (Fig. 3D) 
(39–41). In contrast, Ser515 is unique to human JAK1 and would be predicted to only form a 
weak consensus for AMPK substrate recognition if Ser518 became negatively charged by 
phosphorylation (Fig. 3C). However other examples of AMPK substrates that only loosely 
follow the optimized consensus [such as Ser633 in endothelial constitutive nitric oxide synthase 
(42)] have also been documented. Thus we examined a potential role for both Ser515 and Ser518 in 
more detail. 
AMPK mediates the phosphorylation of JAK1 in intact cells 
A common mechanism for phosphorylation-mediated regulation of target protein function is 
phosphorylation-dependent binding to members of the 14-3-3 family of proteins (43). To assess 
whether phosphorylation of Ser515 and Ser518 could facilitate JAK1 interaction with 14-3-3 
proteins in vitro, overlay assays were performed with horseradish peroxidase (HRP)-conjugated 
14-3-3ζ (HRP-14-3-3ζ)and peptide arrays comprising 25-mer peptides from the identified JAK1 
region in which either or both of Ser515 and Ser518 were phosphorylated (Fig. 4A). These 
demonstrated that phospho-Ser515 and phospho-Ser518 peptides strongly interacted with HRP-14-
3-3ζ in vitro, whereas no binding was detectable with either non-phosphorylated peptide or 
peptide in which both Ser515 and Ser518 were phosphorylated (Fig. 4A). 
A phosphorylation-dependent interaction with 14-3-3 proteins has been reported for several 
AMPK substrates, including autophagy-related protein 9 (ATG9), Raptor, and Unc-51-like 
autophagy activating kinase 1 (ULK1) (44)(38)(45). We tested our ability to detect such 
interaction using two approaches. First, we compared the ability of bacterially expressed and 
affinity purified glutathione S-transferase (GST)/14-3-3 fusion proteins to capture AMPK-
phosphorylated JAK1 in pull-down assays from soluble extracts prepared from intact cells. 
Initial experiments in JAK1-null U4C human fibrosarcoma cells stably expressing recombinant 
JAK1 (46)(47) demonstrated that distinct GST/14-3-3 isoforms (14-3-3ζ and 14-3-3τ) but not 
GST alone could specifically isolate JAK1 (fig. S4). To assess the importance of Ser515 and 
Ser518 in mediating this interaction, we used a different approach in which wild-type and 
S515A/S518A (SSAA)-mutated human JAK1 were transiently expressed in U4C cells before 
JAK1 was immunoprecipitated and resulting blots were overlaid with HRP-14-3-3ζ. Consistent 
with the peptide array overlays, these experiments demonstrated that whereas wild-type JAK1 
could be specifically identified, the SSAA-mutated JAK1 could not, despite equivalent 
abundances of JAK1 in the immunoprecipitates (fig. S4). Finally, to assess the role of AMPK 
activation on JAK1 phosphorylation in intact cells, wild-type and SSAA-mutated human JAK1 
were transiently expressed in U4C cells before treatment with A769662 and preparation of cell 
extracts for pull-down assays with GST/14-3-3ζ and immunoblotting for JAK1 (Fig. 4B). These 
demonstrated that A769662 treatment increased 14-3-3ζ interaction with JAK1 but not SSAA-
mutant JAK1, despite an apparently equivalent activation of AMPK and expression of wild-type 
and mutant JAK1 in transfected cells (Fig. 4B). 
To further examine the AMPK dependence of this effect, GST/14-3-3ζ pull downs were 
performed in wild-type murine embryonic fibroblasts (MEFs) and MEFs with no detectable 
AMPK activity due to homozygous deletion of AMPKα1 and α2 catalytic subunits (48). AMPK 
activation with A769662 in wild-type MEFs transiently increased interaction of endogenous 
JAK1 with GST/14-3-3ζ but this effect was absent in cells devoid of AMPK activity as 
determined by the loss of ACC phosphorylation on Ser79 (Fig. 4C). Because murine JAK1 lacks 
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Ser515 or an equivalent residue (Fig. 3C), this suggests that phosphorylation of Ser517 alone on 
murine JAK1 is required for interaction with GST/14-3-3ζ. Finally, we examined the effects of 
combined metformin and salicylate treatment on AMPK-mediated JAK1 phosphorylation (as 
determined by interaction with GST/14-3-3ζ) in HUVECs, a condition which we had found 
significantly inhibited sIL-6Rα/IL-6-stimulated STAT3 phosphorylation (Fig. 1A). Combined 
treatment of HUVECs with metformin and salicylate significantly increased ACC 
phosphorylation and triggered a transient increase in the amount of endogenous JAK1 that was 
captured by GST/14-3-3ζ, which peaked approximately1 hour after stimulation (Fig. 4D). 
AMPK-mediated inhibition of JAK1-dependent signaling requires Ser515 and Ser518 
To investigate any contribution of AMPK-mediated JAK1 phosphorylation on Ser515 and Ser518 
towards regulating signaling, we utilized JAK1-null U4C human fibrosarcoma cells. Consistent 
with previous work (46) and our own siRNA experiments in HUVECs, loss of JAK1 was 
associated with no detectable sIL-Rα/IL-6-mediated phosphorylation of STAT3. However, 
transient expression of wild-type human JAK1 restored sIL-Rα/IL-6-mediated STAT3 
phosphorylation over GFP-expressing controls, and this was inhibited by pre-treatment with 
A769662 similar to the phenomenon observed in HUVECs (Fig. 5A). Expression of SSAA-
mutant JAK1 in U4C cells was also able to restore sIL-Rα/IL-6-mediated STAT3 
phosphorylation, but the ability of A769662 to inhibit this effect was lost despite maintaining its 
ability to activate AMPK as measured by ACC phosphorylation (Fig. 5B). 
We then examined the effects of AMPK activation on signaling downstream of a constitutively 
active V658F-mutant version of JAK1 found in patients with acute lymphoblastic leukemia 
(ALL) (49). Analogous to the V617F mutation in JAK2, which is implicated in the etiology of 
several myeloproliferative neoplasms, this mutation within the JAK1 JH2 pseudokinase domain 
is thought to relieve an auto-inhibitory interaction with the catalytic JH1 domain, thereby 
increasing Tyr kinase activity independently of cytokine stimulation (1)(50). In contrast to wild-
type JAK1, transient expression of V658F-mutant JAK1 in JAK1-null U4C cells was sufficient 
to trigger detectable Tyr phosphorylation of both STAT1 and STAT3 in the absence of added 
cytokine (Fig. 5C). Exposing cells to A769662 increased ACC phosphorylation and inhibited 
STAT1 and STAT3 Tyr phosphorylation. Expression of V658F-mutant JAK1 incorporating the 
S515A/S518A (SSAA) mutations also resulted in increased basal STAT phosphorylation, 
although this effect was less than that caused by V658F-mutant JAK1 expression. However, 
A769662 treatment failed to significantly inhibit Tyr phosphorylation of STAT1 and STAT3 
despite increasing ACC phosphorylation (Fig. 5C). Together, these observations suggest that 
Ser515 and Ser518 in JAK1 are required for effective AMPK-mediated inhibition of JAK1-
mediated downstream signaling to STAT1 and STAT3. 
 
Discussion 
It is becoming increasingly apparent that cells can couple inflammatory status to the availability 
of nutrients (51)(52). Conversely, the mechanisms by which nutrient availability can regulate 
inflammation remain unclear. In this study we demonstrate that direct phosphorylation of JAK1, 
a key signaling intermediate utilized by a variety of cytokines, can occur in response to 
stimulation of AMPK, a key determinant of cellular energy status, by multiple activators. In 
conjunction with other observations, this would suggest that energy stress triggers an LKB1-
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dependent activation of AMPK that can inhibit the JAK-STAT pathway through several distinct 
mechanisms. For example, others have shown that chronic AMPK activation in hepatocytes with 
metformin for 12 hr is able to increase levels of the orphan nuclear receptor small heterodimer 
partner (SHP), which reduces STAT3 phosphorylation on Tyr705 and co-localizes with nuclear 
STAT3 to reduce its binding to target gene promoters (53)(54). Similarly, others have 
demonstrated that chronic treatment of hepatocytes with AICAR suppresses IL-6 signaling, and  
was thought to involve an AMPK-mediated inhibition of IL-6-stimulated Tyr phosphorylation 
and activation of JAK1 and JAK2, and that depletion of AMPKα1 and α2 subunits could block 
the inhibitory effects of AMPK activators on cytokine-stimulated signaling without significantly 
altering basal activation (55)(56). However the underlying mechanisms were not investigated. 
Finally, a role for AMPK-mediated induction of mitogen-activated protein kinase phosphatase-1 
(MKP-1) has been reported to play a critical role in suppressing STAT1 activation in aortic 
smooth muscle cells (57). In contrast, we have demonstrated that AMPK-mediated 
phosphorylation of JAK1 within its regulatory SH2 domain is a rapid event mediated by direct 
AMPK activators (A769662, salicylate) and mitochondrial inhibitors (metformin) and is required 
for AMPK to inhibit STAT3 activation by IL-6 in multiple cell systems. The location of the 
conserved Ser518 residue at the start of the αB helix within the JAK1 SH2 domain (39) suggests 
that phosphorylation may disrupt SH2 domain structure sufficiently to uncouple cytokine 
receptors from JAK1 activation, although this has yet to be tested. We also found that either 
AMPKα1 knockdown or AV-mediated expression of dominant negative AMPKα1 specifically 
blocked the ability of AMPK activators to suppress STAT, thereby ruling out a constitutive 
suppressive effect of AMPK on JAK-STAT signaling under our conditions. Finally, the 
existence of several inhibitory mechanisms by which AMPK can suppress JAK-STAT signaling 
mirrors the multi-faceted impact of AMPK on the mTOR signaling pathway, which it inhibits 
through direct phosphorylation of two components [tuberous sclerosis complex 2 (TSC2) on 
Ser1387 (58)(59) and Raptor on Ser722 and Ser792 (38)]. These observations suggest that, like the 
mTOR pathway, AMPK-mediated regulation of JAK-STAT signaling has also evolved such that 
multiple mechanisms and targets are used to limit its activation. 
Given the importance of AMPK and JAK-STAT signaling pathways in either inhibiting or 
stimulating processes such as cell proliferation, longevity, angiogenesis and inflammation, 
AMPK-mediated JAK1 phosphorylation could potentially influence these events. Several studies 
have reported that LKB1, the major kinase responsible for activation loop phosphorylation of 
AMPKα subunits in response to energy stress, exerts a suppressive effect on STAT3 
phosphorylation and function, such that loss of LKB1 increases STAT3 phosphorylation 
(60)(61)(62). LKB1 is a tumor suppressor and is frequently inactivated in human cancers (63), 
while hyperactivation of STAT3 within tumor cells and the tumor microenvironment has been 
extensively described (18). The identification of JAK1 as a target would suggest that AMPK 
activation might be a useful strategy for limiting STAT3-mediated tumor progression, in addition 
to its well described effects on cell growth, proliferation and autophagy (45)(38)(64). The ability 
of AMPK to inhibit STAT phosphorylation following expression of a constitutively active 
V658F-mutant of JAK1 through a mechanism requiring Ser515 or Ser518 would also support 
clinical studies to evaluate AMPK activators such as metformin as potential treatment options for 
patients with ALL caused by activating JAK1 mutations (49)(65). 
 
Materials and Methods 
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Materials 
Antibodies against JAK1 were from BD Transduction Laboratories (cat. no. 610232). HRP-
conjugated antibodies against GST were from Abcam (cat. no. ab3416). Cytokines and HRP-
conjugated 14-3-3ζ were from R&D Systems. Other antibodies used have been described 
elsewhere (66)(67)(68)(21)(69). Peptide arrays were synthesized on glass slides by automatic 
SPOT synthesis using Fmoc (9-fluorenylmethyloxycarbonyl) chemistry with the AutoSpot-
Robot ASS 222 (Intavis Bioanalytical Instruments). AMPK preparations used for in vitro kinase 
assays were purified from rat liver as previously described (35). Ad5 adenoviruses expressing 
either GFP (AV.GFP) or a dominant negative mutant AMPKα1 (AV.DN-AMPKα1) were 
prepared, titered and used to infect HUVECs as described previously(28)(68)(70) 
Cell culture and transfections 
SV40-immortalised wild-type and PRKAA1-/-/PRKAA2-/- MEFs lacking AMPKα1 and AMPKα2 
catalytic subunits, HUVECs, U937 promonocytic cells and the human fibrosarcoma cell lines 
2C4, U4C and U4C.JAK1 were cultured as previously described (34)(47)(48)(21)(71). Transient 
expression of wild type and mutated JAK1 constructs in U4C cells was performed using 
PolyFect transfection reagent (Qiagen) in accordance with the manufacturer’s instructions. 
Transfection of HUVECs with siRNAs was performed as we have previously described (71)(72). 
Expression constructs 
pGEX4T/14-3-3ζ was obtained from Professor Graeme Milligan (University of Glasgow, UK). 
C-terminally Flag- and myc epitope-tagged human JAK1 in pCMV6 was obtained from Origene 
(cat. no. RC213878). QuikChange mutagenesis (Agilent Technologies) was used to introduce 
JAK1 mutations at Ser515 and Ser518 to Ala, and Val658 to Phe. All constructs were sequenced in 
their entirety to ensure that no additional unanticipated mutations had been introduced. 
SDS-PAGE, immunoblotting and overlays 
Cells were washed twice with ice-cold PBS and lysed by scraping into lysis buffer [50 mM 
HEPES pH 7.4, 150 mM sodium chloride, 1% (v/v) Triton X-100, 0.5% (v/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 10 mM sodium fluoride, 5mM EDTA, 10 mM sodium 
phosphate, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml benzamidine, 10 µg/ml 
soybean trypsin inhibitor, 2% (w/v) EDTA-free complete protease inhibitor cocktail (Sigma)]. 
After 30 min on ice, lysates were vortexed and cleared by centrifugation.  Equivalent amounts of 
protein, as determined by bicinchoninic acid protein assay, were fractionated by 8 to 12% SDS-
PAGE gels depending on the application, transferred to a nitrocellulose membrane and analyzed 
either by immunoblotting or overlay with HRP-14-3-3ζ as previously described (68)(71). Peptide 
arrays were blocked in 5% (w/v) BSA in Tris-buffered saline containing 0.1% (v/v) Tween-20 
(TBST) prior to overlay with HRP-14-3-3ζ (1:500 in BSA/TBST) overnight at 4oC, washing and 
visualization by enhanced chemiluminescence. 
Peptide array AMPK assays 
Peptide arrays were synthesized as previously described (73) AMPK phosphorylation of 
immobilized peptide arrays spotted in duplicate was undertaken with either vehicle or 0.5 
units/ml of purified rat liver AMPK (35) diluted in phosphorylation buffer (50 mM HEPES, 
pH7.4, 0.01% (v/v) Brij-35, 1 mM DTT, 1 mM ATP, 0.2 mM AMP, 25 mM MgCl2, 1% (w/v) 
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BSA) containing 1 µCi [γ32P]ATP followed by incubation at 30°C for 30 min. Phosphorylated 
peptides were visualized by autoradiography. 
Pull-down assays and immunoprecipitations 
Recombinant GST, GST/14-3-3τ and GST/14-3-3ζ were produced following induction in E. coli 
BL21 cells and purified from clarified bacterial extracts using glutathione-Sepharose beads. 20 
µg of GST, GST/14-3-3τ or GST/14-3-3ζ immobilized on glutathione-Sepharose beads were 
added to protein-equalized clarified cell extracts prepared in pull down assay buffer (50 mM 
HEPES, pH 7.4, 120 mM NaCl, 5 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 
supplemented with phosphatase inhibitors 5mM sodium fluoride, 1mM sodium orthovanadate, 
and protease inhibitors 10 µg/ml benzamidine, 0.1mM PMSF, 10 µg/ml soybean trypsin 
inhibitor, 2% (w/v) EDTA-free complete protease inhibitor cocktail) and incubated overnight 
with rotation at 4oC. After washing three times in pull down assay buffer, samples were eluted in 
SDS-PAGE sample buffer by incubation at 65oC for 30 min prior to fractionation on 8% SDS-
PAGE gels and immunoblotting with an antibody against JAK1. GST fusion proteins were 
identified either by probing with HRP-conjugated antibody against GST or Ponceau staining of 
nitrocellulose blots. 
Flag-tagged wild type and mutated human JAK1 were immunoprecipitated from transfected U4C 
cells solubilized in immunoprecipitation buffer using Flag M2-Sepharose beads prior to analysis 
by SDS-PAGE and immunoblotting as previously described (73).  
Analysis of conditioned medium for chemotactic activity 
Conditioned medium was obtained from HUVECs pre-incubated in the presence or absence of 
100 µM A769662 for 30 min prior to incubation with 25 ng/ml sIL-6Rα and 5 ng/ml IL-6 for 2 
h. HUVECs were washed prior to collection of conditioned medium for 1h (such that residual 
sIL-6Rα/IL-6 and A769662 were not in conditioned medium). Conditioned medium from each 
treatment was then added to the bottom wells of a Boyden chamber and equal numbers of U937 
promonocytic cells added to the top chamber, which was separated from the bottom by a 
collagen-coated membrane. After 5 hr, migrated U937 cells were collected from the lower well 
and counted in urinalysis glasstic slides (Stratagene, Cambridge, UK). 
Statistical Analysis 
Results are expressed as mean ± SEM. Statistically significant differences were determined using 
a two-tail t-test, or one or two-way ANOVA where appropriate, with p < 0.05 as significant. 
 
Supplementary Materials 
Fig. S1. AMPK-mediated inhibition of STAT3 phosphorylation in HUVECs. 
Fig. S2. AMPK-mediated inhibition of sIL-6Rα/IL-6-stimulated SOCS3 and CEBPD mRNA 
induction. 
Fig. S3. Contributions of JAK1, JAK2 and Tyk2 in mediating sIL-6Rα/IL-6-mediated STAT3 
phosphorylation in HUVECs. 
Fig. S4. Specific interaction of JAK1 with 14-3-3ζ and 14−3−3τ. 
11 
 
 
References and Notes 
1. J. J. O’Shea, D. M. Schwartz, A. V Villarino, M. Gadina, I. B. McInnes, A. Laurence, The 
JAK-STAT pathway: impact on human disease and therapeutic intervention., Annu. Rev. Med. 
66, 311–28 (2015). 
2. C. Garbers, H. M. Hermanns, F. Schaper, G. Müller-Newen, J. Grötzinger, S. Rose-John, J. 
Scheller, Plasticity and cross-talk of interleukin 6-type cytokines., Cytokine Growth Factor Rev. 
23, 85–97 (2012). 
3. S. A. Jones, J. Scheller, S. Rose-John, Therapeutic strategies for the clinical blockade of IL-
6/gp130 signaling., J. Clin. Invest. 121, 3375–83 (2011). 
4. R. Eulenfeld, A. Dittrich, C. Khouri, P. J. Müller, B. Mütze, A. Wolf, F. Schaper, Interleukin-
6 signalling: more than Jaks and STATs., Eur. J. Cell Biol. 91, 486–95 (2012). 
5. D. G. Hardie, AMP-activated protein kinase: maintaining energy homeostasis at the cellular 
and whole-body levels., Annu. Rev. Nutr. 34, 31–55 (2014). 
6. G. R. Steinberg, B. E. Kemp, AMPK in Health and Disease., Physiol. Rev. 89, 1025–78 
(2009). 
7. L. Tong, Structure and function of biotin-dependent carboxylases, Cell. Mol. Life Sci. 70, 863–
891 (2013). 
8. K. Marcinko, G. R. Steinberg, The role of AMPK in controlling metabolism and 
mitochondrial biogenesis during exercise, Exp. Physiol. 99, 1581–1585 (2014). 
9. E. Bess, B. Fisslthaler, T. Frömel, I. Fleming, Nitric oxide-induced activation of the AMP-
activated protein kinase α2 subunit attenuates IκB kinase activity and inflammatory responses in 
endothelial cells., PLoS One 6, e20848 (2011). 
10. B. Gongol, T. Marin, I.-C. Peng, B. Woo, M. Martin, S. King, W. Sun, D. A. Johnson, S. 
Chien, J. Y.-J. Shyy, AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6., 
Proc. Natl. Acad. Sci. U. S. A. 110, 3161–6 (2013). 
11. F. S. Gaskin, K. Kamada, M. Y. Zuidema, A. W. Jones, L. J. Rubin, R. J. Korthuis, Isoform-
selective 5’-AMP-activated protein kinase-dependent preconditioning mechanisms to prevent 
postischemic leukocyte-endothelial cell adhesive interactions., Am. J. Physiol. Heart Circ. 
Physiol. 300, H1352–60 (2011). 
12. S. Schuhmacher, M. Foretz, M. Knorr, T. Jansen, M. Hortmann, P. Wenzel, M. Oelze, A. L. 
Kleschyov, A. Daiber, J. F. Keaney, G. Wegener, K. Lackner, T. Münzel, B. Viollet, E. Schulz, 
α1AMP-activated protein kinase preserves endothelial function during chronic angiotensin II 
treatment by limiting Nox2 upregulation., Arterioscler. Thromb. Vasc. Biol. 31, 560–6 (2011). 
13. A. Bai, M. Yong, A. G. Ma, Y. Ma, C. R. Weiss, Q. Guan, C. N. Bernstein, Z. Peng, Novel 
anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective 
effect in dextran sulfate sodium-induced acute and chronic colitis., J. Pharmacol. Exp. Ther. 333, 
717–25 (2010). 
14. X. Zhao, J. W. Zmijewski, E. Lorne, G. Liu, Y.-J. Park, Y. Tsuruta, E. Abraham, Activation 
of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung 
12 
 
injury., Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L497–504 (2008). 
15. R. Prasad, S. Giri, N. Nath, I. Singh, A. K. Singh, 5-aminoimidazole-4-carboxamide-1-beta-
4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of 
endothelial-monocyte interaction., J. Neurosci. Res. 84, 614–25 (2006). 
16. S. Galic, M. D. Fullerton, J. D. Schertzer, S. Sikkema, K. Marcinko, C. R. Walkley, D. Izon, 
J. Honeyman, Z.-P. Chen, B. J. van Denderen, B. E. Kemp, G. R. Steinberg, Hematopoietic 
AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in 
obesity., J. Clin. Invest. 121, 4903–15 (2011). 
17. Y. Zhang, J. Qiu, X. Wang, Y. Zhang, M. Xia, AMP-activated protein kinase suppresses 
endothelial cell inflammation through phosphorylation of transcriptional coactivator p300., 
Arterioscler. Thromb. Vasc. Biol. 31, 2897–908 (2011). 
18. H. Yu, H. Lee, A. Herrmann, R. Buettner, R. Jove, Revisiting STAT3 signalling in cancer: 
new and unexpected biological functions, Nat. Rev. Cancer 14, 736–746 (2014). 
19. W. Vainchenker, S. N. Constantinescu, JAK/STAT signaling in hematological malignancies., 
Oncogene 32, 2601–13 (2013). 
20. G. Ortiz-Muñoz, J. L. Martin-Ventura, P. Hernandez-Vargas, B. Mallavia, V. Lopez-Parra, 
O. Lopez-Franco, B. Muñoz-Garcia, P. Fernandez-Vizarra, L. Ortega, J. Egido, C. Gomez-
Guerrero, Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses 
during atherosclerosis., Arterioscler. Thromb. Vasc. Biol. 29, 525–31 (2009). 
21. M.-A. Ewart, C. F. Kohlhaas, I. P. Salt, Inhibition of tumor necrosis factor alpha-stimulated 
monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase., 
Arterioscler. Thromb. Vasc. Biol. 28, 2255–7 (2008). 
22. B. Enkhjargal, S. Godo, A. Sawada, N. Suvd, H. Saito, K. Noda, K. Satoh, H. Shimokawa, 
Endothelial AMP-activated protein kinase regulates blood pressure and coronary flow responses 
through hyperpolarization mechanism in mice., Arterioscler. Thromb. Vasc. Biol. 34, 1505–13 
(2014). 
23. J. M. Corton, J. G. Gillespie, S. A. Hawley, D. G. Hardie, 5-Aminoimidazole-4-Carboxamide 
Ribonucleoside. A Specific Method for Activating AMP-Activated Protein Kinase in Intact 
Cells?, Eur. J. Biochem. 229, 558–565 (1995). 
24. J. W. Scott, B. J. W. van Denderen, S. B. Jorgensen, J. E. Honeyman, G. R. Steinberg, J. S. 
Oakhill, T. J. Iseli, A. Koay, P. R. Gooley, D. Stapleton, B. E. Kemp, Thienopyridone drugs are 
selective activators of AMP-activated protein kinase beta1-containing complexes., Chem. Biol. 
15, 1220–30 (2008). 
25. M. R. Owen, E. Doran, A. P. Halestrap, Evidence that metformin exerts its anti-diabetic 
effects through inhibition of complex 1 of the mitochondrial respiratory chain., Biochem. J. 348 
Pt 3, 607–14 (2000). 
26. S. A. Hawley, M. D. Fullerton, F. A. Ross, J. D. Schertzer, C. Chevtzoff, K. J. Walker, M. 
W. Peggie, D. Zibrova, K. A. Green, K. J. Mustard, B. E. Kemp, K. Sakamoto, G. R. Steinberg, 
D. G. Hardie, The ancient drug salicylate directly activates AMP-activated protein kinase., 
Science 336, 918–22 (2012). 
27. R. J. Ford, M. D. Fullerton, S. L. Pinkosky, E. A. Day, J. W. Scott, J. S. Oakhill, A. L. Bujak, 
13 
 
B. K. Smith, J. D. Crane, R. M. Blümer, K. Marcinko, B. E. Kemp, H. C. Gerstein, G. R. 
Steinberg, Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and 
improve insulin sensitivity., Biochem. J. 468, 125–32 (2015). 
28. A. Woods, D. Azzout-Marniche, M. Foretz, S. C. Stein, P. Lemarchand, P. Ferre, F. Foufelle, 
D. Carling, Characterization of the Role of AMP-Activated Protein Kinase in the Regulation of 
Glucose-Activated Gene Expression Using Constitutively Active and Dominant Negative Forms 
of the Kinase, Mol. Cell. Biol. 20, 6704–6711 (2000). 
29. J. Yang, J. Huang, M. Dasgupta, N. Sears, M. Miyagi, B. Wang, M. R. Chance, X. Chen, Y. 
Du, Y. Wang, L. An, Q. Wang, T. Lu, X. Zhang, Z. Wang, G. R. Stark, Reversible methylation 
of promoter-bound STAT3 by histone-modifying enzymes., Proc. Natl. Acad. Sci. U. S. A. 107, 
21499–504 (2010). 
30. C. A. Cantwell, E. Sterneck, P. F. Johnson, Interleukin-6-Specific Activation of the C/EBPδ 
Gene in Hepatocytes Is Mediated by Stat3 and Sp1, Mol. Cell. Biol. 18, 2108–2117 (1998). 
31. M. Jougasaki, T. Ichiki, Y. Takenoshita, M. Setoguchi, Statins suppress interleukin-6-
induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and 
activators of transcription pathways in human vascular endothelial cells., Br. J. Pharmacol. 159, 
1294–303 (2010). 
32. M. Romano, M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. 
Luini, V. van Hinsbergh, S. Sozzani, F. Bussolino, V. Poli, G. Ciliberto, A. Mantovani, Role of 
IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment, Immunity 
6, 315–325 (1997). 
33. E. C. Borden, G. C. Sen, G. Uze, R. H. Silverman, R. M. Ransohoff, G. R. Foster, G. R. 
Stark, Interferons at age 50: past, current and future impact on biomedicine., Nat. Rev. Drug 
Discov. 6, 975–90 (2007). 
34. M. C. Gauzzi, L. Velazquez, R. McKendry, K. E. Mogensen, M. Fellous, S. Pellegrini, 
Interferon- -dependent Activation of Tyk2 Requires Phosphorylation of Positive Regulatory 
Tyrosines by Another Kinase, J. Biol. Chem. 271, 20494–20500 (1996). 
35. S. A. Hawley, M. Davison, A. Woods, S. P. Davies, R. K. Beri, D. Carling, D. G. Hardie, 
Characterization of the AMP-activated Protein Kinase Kinase from Rat Liver and Identification 
of Threonine 172 as the Major Site at Which It Phosphorylates AMP-activated Protein Kinase, J. 
Biol. Chem. 271, 27879–27887 (1996). 
36. K. M. Brown, L. C. Y. Lee, J. E. Findlay, J. P. Day, G. S. Baillie, Cyclic AMP-specific 
phosphodiesterase, PDE8A1, is activated by protein kinase A-mediated phosphorylation., FEBS 
Lett. 586, 1631–7 (2012). 
37. J. W. Scott, D. G. Norman, S. A. Hawley, L. Kontogiannis, D. G. Hardie, Protein kinase 
substrate recognition studied using the recombinant catalytic domain of AMP-activated protein 
kinase and a model substrate., J. Mol. Biol. 317, 309–23 (2002). 
38. D. M. Gwinn, D. B. Shackelford, D. F. Egan, M. M. Mihaylova, A. Mery, D. S. Vasquez, B. 
E. Turk, R. J. Shaw, AMPK phosphorylation of raptor mediates a metabolic checkpoint., Mol. 
Cell 30, 214–26 (2008). 
39. R. Ferrao, H. J. A. Wallweber, H. Ho, C. Tam, Y. Franke, J. Quinn, P. J. Lupardus, The 
14 
 
Structural Basis for Class II Cytokine Receptor Recognition by JAK1., Structure 24, 897–905 
(2016). 
40. R. McNally, A. V. Toms, M. J. Eck, T. J. Boggon, Ed. Crystal Structure of the FERM-SH2 
Module of Human Jak2, PLoS One 11, e0156218 (2016). 
41. H. J. A. Wallweber, C. Tam, Y. Franke, M. A. Starovasnik, P. J. Lupardus, Structural basis 
of recognition of interferon-α receptor by tyrosine kinase 2., Nat. Struct. Mol. Biol. 21, 443–8 
(2014). 
42. Z. Chen, I.-C. Peng, W. Sun, M.-I. Su, P.-H. Hsu, Y. Fu, Y. Zhu, K. DeFea, S. Pan, M.-D. 
Tsai, J. Y.-J. Shyy, AMP-activated protein kinase functionally phosphorylates endothelial nitric 
oxide synthase Ser633., Circ. Res. 104, 496–505 (2009). 
43. D. Bridges, G. B. G. Moorhead, 14-3-3 proteins: a number of functions for a numbered 
protein., Sci. STKE 2005, re10 (2005). 
44. V. K. Weerasekara, D. J. Panek, D. G. Broadbent, J. B. Mortenson, A. D. Mathis, G. N. 
Logan, J. T. Prince, D. M. Thomson, J. W. Thompson, J. L. Andersen, Metabolic-stress-induced 
rearrangement of the 14-3-3ζ interactome promotes autophagy via a ULK1- and AMPK-
regulated 14-3-3ζ interaction with phosphorylated Atg9., Mol. Cell. Biol. 34, 4379–88 (2014). 
45. H. I. D. Mack, B. Zheng, J. M. Asara, S. M. Thomas, AMPK-dependent phosphorylation of 
ULK1 regulates ATG9 localization., Autophagy 8, 1197–214 (2012). 
46. M. Müller, J. Briscoe, C. Laxton, D. Guschin, A. Ziemiecki, O. Silvennoinen, A. G. Harpur, 
G. Barbieri, B. A. Witthuhn, C. Schindler, The protein tyrosine kinase JAK1 complements 
defects in interferon-alpha/beta and -gamma signal transduction., Nature 366, 129–35 (1993). 
47. D. Guschin, N. Rogers, J. Briscoe, B. Witthuhn, D. Watling, F. Horn, S. Pellegrini, K. 
Yasukawa, P. Heinrich, G. R. Stark, A major role for the protein tyrosine kinase JAK1 in the 
JAK/STAT signal transduction pathway in response to interleukin-6., EMBO J. 14, 1421–9 
(1995). 
48. K. R. Laderoute, K. Amin, J. M. Calaoagan, M. Knapp, T. Le, J. Orduna, M. Foretz, B. 
Viollet, 5’-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose 
deprivation conditions found in solid-tumor microenvironments., Mol. Cell. Biol. 26, 5336–47 
(2006). 
49. C. G. Mullighan, J. Zhang, R. C. Harvey, J. R. Collins-Underwood, B. A. Schulman, L. A. 
Phillips, S. K. Tasian, M. L. Loh, X. Su, W. Liu, M. Devidas, S. R. Atlas, I.-M. Chen, R. J. 
Clifford, D. S. Gerhard, W. L. Carroll, G. H. Reaman, M. Smith, J. R. Downing, S. P. Hunger, C. 
L. Willman, JAK mutations in high-risk childhood acute lymphoblastic leukemia., Proc. Natl. 
Acad. Sci. U. S. A. 106, 9414–8 (2009). 
50. O. Silvennoinen, S. R. Hubbard, Molecular insights into regulation of JAK2 in 
myeloproliferative neoplasms., Blood 125, 3388–92 (2015). 
51. L. A. J. O’Neill, D. G. Hardie, Metabolism of inflammation limited by AMPK and pseudo-
starvation., Nature 493, 346–55 (2013). 
52. M. Dandapani, D. G. Hardie, AMPK: opposing the metabolic changes in both tumour cells 
and inflammatory cells?, Biochem. Soc. Trans. 41, 687–93 (2013). 
15 
 
53. Y. D. Kim, Y. H. Kim, Y. M. Cho, D. K. Kim, S. W. Ahn, J. M. Lee, D. Chanda, M. Shong, 
C. H. Lee, H. S. Choi, Metformin ameliorates IL-6-induced hepatic insulin resistance via 
induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models., 
Diabetologia 55, 1482–94 (2012). 
54. Y. D. Kim, Y.-H. Kim, S. Tadi, J. H. Yu, Y.-H. Yim, N. H. Jeoung, M. Shong, L. 
Hennighausen, R. A. Harris, I.-K. Lee, C.-H. Lee, H.-S. Choi, Metformin inhibits growth 
hormone-mediated hepatic PDK4 gene expression through induction of orphan nuclear receptor 
small heterodimer partner., Diabetes 61, 2484–94 (2012). 
55. A. Nerstedt, E. Cansby, M. Amrutkar, U. Smith, M. Mahlapuu, Pharmacological activation 
of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in 
human hepatocytes., Mol. Cell. Endocrinol. 375, 68–78 (2013). 
56. A. Nerstedt, A. Johansson, C. X. Andersson, E. Cansby, U. Smith, M. Mahlapuu, AMP-
activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by 
suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3), 
Diabetologia 53, 2406–2416 (2010). 
57. C. He, H. Li, B. Viollet, M.-H. Zou, Z. Xie, AMP-activated Protein Kinase Suppresses 
Vascular Inflammation in vivo by Inhibiting Signal Transducer and Activator of Transcription-
1., Diabetes (2015), doi:10.2337/db15-0107. 
58. K. Inoki, T. Zhu, K.-L. Guan, TSC2 Mediates Cellular Energy Response to Control Cell 
Growth and Survival, Cell 115, 577–590 (2003). 
59. R. J. Shaw, N. Bardeesy, B. D. Manning, L. Lopez, M. Kosmatka, R. A. DePinho, L. C. 
Cantley, The LKB1 tumor suppressor negatively regulates mTOR signaling., Cancer Cell 6, 91–
9 (2004). 
60. A. Mukhopadhyay, K. C. Berrett, U. Kc, P. M. Clair, S. M. Pop, S. R. Carr, B. L. Witt, T. G. 
Oliver, Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer., Cell 
Rep. 8, 40–9 (2014). 
61. Y. Wang, W. Dai, X. Chu, B. Yang, M. Zhao, Y. Sun, Downregulation of LKB1 suppresses 
Stat3 activity to promote the proliferation of esophageal carcinoma cells, Mol. Med. Rep. 9, 
2400–2404 (2014). 
62. D. W. Kim, H. K. Chung, K. C. Park, J. H. Hwang, Y. S. Jo, J. Chung, D. V Kalvakolanu, N. 
Resta, M. Shong, Tumor suppressor LKB1 inhibits activation of signal transducer and activator 
of transcription 3 (STAT3) by thyroid oncogenic tyrosine kinase rearranged in transformation 
(RET)/papillary thyroid carcinoma (PTC)., Mol. Endocrinol. 21, 3039–49 (2007). 
63. M. Momcilovic, D. B. Shackelford, Targeting LKB1 in cancer - exposing and exploiting 
vulnerabilities., Br. J. Cancer 113, 574–84 (2015). 
64. D. F. Egan, D. B. Shackelford, M. M. Mihaylova, S. Gelino, R. A. Kohnz, W. Mair, D. S. 
Vasquez, A. Joshi, D. M. Gwinn, R. Taylor, J. M. Asara, J. Fitzpatrick, A. Dillin, B. Viollet, M. 
Kundu, M. Hansen, R. J. Shaw, Phosphorylation of ULK1 (hATG1) by AMP-activated protein 
kinase connects energy sensing to mitophagy., Science 331, 456–61 (2011). 
65. E. Flex, V. Petrangeli, L. Stella, S. Chiaretti, T. Hornakova, L. Knoops, C. Ariola, V. Fodale, 
E. Clappier, F. Paoloni, S. Martinelli, A. Fragale, M. Sanchez, S. Tavolaro, M. Messina, G. 
16 
 
Cazzaniga, A. Camera, G. Pizzolo, A. Tornesello, M. Vignetti, A. Battistini, H. Cavé, B. D. 
Gelb, J.-C. Renauld, A. Biondi, S. N. Constantinescu, R. Foà, M. Tartaglia, Somatically acquired 
JAK1 mutations in adult acute lymphoblastic leukemia., J. Exp. Med. 205, 751–8 (2008). 
66. W. A. Sands, H. D. Woolson, S. J. Yarwood, T. M. Palmer, Exchange protein directly 
activated by cyclic AMP-1-regulated recruitment of CCAAT/enhancer-binding proteins to the 
suppressor of cytokine signaling-3 promoter., Methods Mol. Biol. 809, 201–14 (2012). 
67. S. J. Yarwood, G. Borland, W. A. Sands, T. M. Palmer, Identification of CCAAT/enhancer-
binding proteins as exchange protein activated by cAMP-activated transcription factors that 
mediate the induction of the SOCS-3 gene., J. Biol. Chem. 283, 6843–53 (2008). 
68. M. M. A. Safhi, C. Rutherford, C. Ledent, W. A. Sands, T. M. Palmer, Priming of signal 
transducer and activator of transcription proteins for cytokine-triggered polyubiquitylation and 
degradation by the A 2A adenosine receptor., Mol. Pharmacol. 77, 968–78 (2010). 
69. J. A. Reihill, M.-A. Ewart, I. P. Salt, The role of AMP-activated protein kinase in the 
functional effects of vascular endothelial growth factor-A and -B in human aortic endothelial 
cells., Vasc. Cell 3, 9 (2011). 
70. W. A. Sands, A. F. Martin, E. W. Strong, T. M. Palmer, Specific Inhibition of Nuclear 
Factor- B-Dependent Inflammatory Responses by Cell Type-Specific Mechanisms upon A2A 
Adenosine Receptor Gene Transfer, Mol. Pharmacol. 66, 1147–1159 (2004). 
71. H. D. Woolson, V. S. Thomson, C. Rutherford, S. J. Yarwood, T. M. Palmer, Selective 
inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via Epac1-
dependent induction of suppressor of cytokine signalling-3., Cell. Signal. 21, 1706–15 (2009). 
72. C. Rutherford, S. Childs, J. Ohotski, L. McGlynn, M. Riddick, S. MacFarlane, D. Tasker, S. 
Pyne, N. J. Pyne, J. Edwards, T. M. Palmer, Regulation of cell survival by sphingosine-1-
phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-
kinase/protein kinase C-mediated upregulation of Mcl-1., Cell Death Dis. 4, e927 (2013). 
73. Y. Y. Sin, T. P. Martin, L. Wills, S. Currie, G. S. Baillie, Small heat shock protein 20 
(Hsp20) facilitates nuclear import of protein kinase D 1 (PKD1) during cardiac hypertrophy., 
Cell Commun. Signal. 13, 16 (2015). 
74. B. Wang, H. Yang, Y.-C. Liu, T. Jelinek, L. Zhang, E. Ruoslahti, H. Fu, Isolation of High-
Affinity Peptide Antagonists of 14-3-3 Proteins by Phage Display †, Biochemistry 38, 12499–
12504 (1999). 
 
Acknowledgments: The authors thank Marcus Rattray and Anne Graham for critically 
reviewing the manuscript. We thank Graeme Milligan (University of Glasgow, UK, for the 
pGEX4T/14-3-3ζ plasmid. 
Funding: T.M.P., I.P.S., G.S.B. and C.D. were supported by project grants from the British 
Heart Foundation (PG/12/1/29276, PG/13/82/30483), Medical Research Council 
(MR/J007412/1), Chief Scientist Office (ETM/226) and an equipment grant from Diabetes UK 
(BDA11/0004309). T.M.P. and C.D. were also supported by project grants from NHS Greater 
Glasgow and Clyde Research Endowment Fund (2011REFCH08) and Chest, Heart and Stroke 
Scotland (R10/A131). A.P.C.-P. was supported by the Experimental Cancer Medicine and 
17 
 
Cancer Research UK Centres at Imperial College, London, U.K. C.S. and S.J.M. were supported 
by PhD studentships from Diabetes UK (BDA11/0004403 [C.S.], BDA09/0003948 [S.J.M.]). 
Author contributions: C.R. and C.S. designed, performed and analyzed the majority of 
experiments. J.J.L.W. designed, performed and analyzed the OSM and LIF experiments. M.-A.E. 
designed, performed and analyzed the chemotaxis experiments. S.J.M. and C.D. advised on the 
study concept and design. G.S.B., B.V., S.A.H. and A.C.-P. advised on aspects of study design 
that used the experimental tools they provided. All listed authors critically revised the manuscript 
and approved the final version. T.M.P. and I.P.S. conceived and designed the study. T.M.P. 
drafted the article, is the guarantor of this work and, as such, had full access to all the data in the 
study and takes responsibility for the integrity of the data and the accuracy of the analysis. 
Competing interests: The authors declare they have no competing interests. 
 
 
 
Figure Legends:  
 
Fig. 1. AMPK rapidly inhibits IL-6 signaling and function. (A) Immunoblotting  of HUVECs 
pre-incubated with vehicle (V), AICAR (1 mM, 2 hours), A769662 (100 µM, 40 min), or 
a combination of metformin and salicylate (Met+Sal; 3 mM and 5 mM,1 hour) then 
stimulated with sIL-6Rα/IL-6 (25 ng/ml, 5 ng/ml) for a further 30 min. Densitometry of 
phosphorylated STAT3 was normalized to that of total protein. Data are mean ±SEM, 
N=3 independent experiments.   (B) Immunoblotting of HUVECs transfected with either 
control or AMPKα1 transcript-targeted siRNA as indicated.  Cells were then pre-
incubated with vehicle or A769662 then stimulated with sIL-6Rα/IL-6 as in (A). Data 
were analyzed as in (A), N=3 independent experiments. (C) Immunoblotting of HUVECs 
pre-treated with vehicle or A769662 (100 µM, 40 min) then stimulated with sIL-6Rα/IL-
6 (25 ng/ml, 5 ng/ml) for 5 hours. Densitometry of SOCS3 and C/EBPδ were normalized 
to GAPDH; N=3 independent experiments. (D) Chemotaxis of U937 promonocytic cells 
cultured in conditioned medium from HUVECs that were pre-treated with vehicle or 
A769662 (100 µM, 30 min) then stimulated with sIL-6Rα/IL-6 (25 ng/ml, 5 ng/ml) for 2 
hours, washed and incubated in fresh medium for conditioning for a further 1 hour. Data 
are mean ±SEM, N=3 independent experiments. *p<0.05 and **p<0.01 using a one-way 
ANOVA with Bonferroni post hoc test.   
 
Fig. 2. AMPK inhibits STAT1 and STAT3 activation by IL-6, LIF, OSM and IFNα. (A) 
Immunoblotting of HUVECs pre-incubated with vehicle (V) or A769662 (100 µM, 30 
min) then stimulated with vehicle (-), sIL-6Rα/IL-6 (25 ng/ml, 5 ng/ml), leukemia 
inhibitory factor (LIF; 10 ng/ml), or oncostatin M (OSM; 10 ng/ml) for 30 min. 
Densitometry of phosphorylated protein was normalized to that of the respective total 
fraction. Data are mean ±SEM from N=4 independent experiments.  **p<0.01 and 
***p<0.001 using a one-way ANOVA with Bonferroni post hoc test. (B) Immunoblotting 
of HUVECs pre-incubated with vehicle (V) or A769662 (100 µM, 30 min) then 
stimulated with vehicle, sIL-6Rα/IL-6 (25 ng/ml/5 ng/ml, 30 min), or IFNα (1000U/ml, 
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15 min). Data were analyzed as in (A); N=3 independent experiments. ***p<0.001 using 
a one-way ANOVA with Bonferroni post hoc test. 
 
Fig. 3. Identification of Ser515 and Ser518 within the JAK1 SH2 domain as sites of AMPK 
phosphorylation in vitro. (A) Overlapping peptide arrays spanning the human JAK1 
open reading frame were incubated with [γ-32P]ATP in the absence (-) or presence (+) of 
AMPK purified from rat liver. Shown are the region of the array in which AMPK-
dependent phosphorylation was detectable (bottom) and the location of the sequence 
within the domain structure of JAK1 (top). Immobilized SAMS peptide on the same array 
served as a control. Data are representative of three experiments. (B) Kinase array as in 
(A) using immobilized comprising wild-type (WT) and S515A/S518A (*) mutant JAK1 
peptides. Italics indicate peptides with no detectable phosphorylation by AMPK. N=3 
experiments. (C) Optimal and secondary selections for AMPK substrate recognition from 
(38) alongside the sequence of rat ACC1 that is phosphorylated by AMPK at Ser79. 
Below: The conformity of the sequence surrounding Ser518 on human JAK1 to the AMPK 
consensus and its evolutionary conservation are shown (color coded), as is the sequence 
surrounding Ser515 in human JAK1. The underlined Ser residue (equivalent to Ser518) 
indicates that this sequence would potentially conform to a weak AMPK consensus site 
after the acquisition of negative charge upon its phosphorylation. (D) Alignment of SH2 
domains from the four human JAK isoforms using T-Coffee then modified to match the 
structural data available for JAK1, JAK2 and Tyk2 (39–41).  For clarity, only the 
alignment of the indicated regions within each SH2 domain is shown. The lettering above 
the alignment indicates secondary structural elements; the βG1 and βG2 regions present 
in the JAK2 and Tyk2 SH2 domains are moderately disordered in the only available 
JAK1 SH2 domain structure (39). The residues corresponding to Ser515 and Ser518 in 
JAK1 are underlined and bolded, and the conserved Ser residues in JAK2, JAK3 and 
Tyk2 equivalent to Ser518 are bolded and marked with an asterisk (*). Box highlights the 
sequence surrounding the conserved Ser residue in each JAK isoform, color coded to 
show conformity to the AMPK consensus. Bottom right: structure of the human JAK1 
FERM-SH2 fusion (PDB: 5IXD) generated using PyMol (39). Zoom: location of Ser518 
within the αB helix immediately downstream of the EF loop in the SH2 domain.  The αA 
and αB loops, present in all SH2 domains, are also indicated. 
 
 
Fig. 4 AMPK-mediated phosphorylation of JAK1 in intact cells. (A) Immobilized peptides 
comprising the indicated JAK1 sequence (top) and variants with phosphorylated (p) and 
non-phosphorylated versions of Ser515 and Ser518 were overlaid with HRP-conjugated 14-
3-3ζ as indicated. Positive and negative control peptides for 14-3-3ζ interaction (74) are 
also shown. Blot is representative of N=3 experiments. (B) JAK1-null U4C human 
fibrosarcoma cells were transiently transfected with wild-type (WT) JAK1, 
S515A/S518A (SSAA) mutant JAK1 constructs, or a control and treated with vehicle (-) 
or A769662 (100 µM) for 40 min. 10% of each total cell extract was immunoblotted as 
indicated; the remainder was incubated with GST/14-3-3ζ and glutathione-Sepharose 
beads, and immunoprecipitates were immunoblotted for JAK1. Densitometry of 
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immunoprecipitated JAK1 was normalized to that in the total extract. Data are mean 
±SEM for N=3 independent experiments. *p<0.05 using a one-way ANOVA with 
Bonferroni post hoc test. (C) Pulldown and immunoblotting as described in (B) in 
immortalized WT and AMPKα1-/-:AMPKα2-/- MEFs treated with A769662 (100 µM) for 
up to 20 min. Data were analyzed as described in (B). *p<0.05 and **p<0.01 using a one-
way ANOVA with Bonferroni post hoc test.  (D) Pulldown and immunoblotting as 
described in (B) in HUVECs treated for the indicated times with metformin and salicylate  
(Met+Sal; 3 and 5 mM, respectively). Data were analyzed as described in (B). *p<0.05 
using a one-way ANOVA with Dunnett post hoc test. 
 
Fig. 5 AMPK-mediated inhibition of JAK1-dependent signaling requires Ser515 and Ser518. 
(A) Immunoblotting in JAK1-null U4C cells transiently transfected with either control 
GFP or wild-type (WT) JAK1 constructs and treated with vehicle (-) or sIL-6Rα/IL-6 (25 
ng/ml, 5 ng/ml) for 30 min after pre-incubation with vehicle (V) or A769662 (100 µM) 
for 40 min. Blots are representative of N=4 experiments. (B) Immunoblotting in U4C 
cells transiently transfected with either WT JAK1 or SSAA-mutant JAK1 and treated 
with vehicle (-) or sIL-6Rα/IL-6 complex (25 ng/ml, 5 ng/ml) for 30 min after pre-
incubation with vehicle or A769662 (100 µM) for 30 min, as indicated.  Line in top blot 
marks where unrelated lanes were removed. Densitometry of phosphorylated STAT3 was 
normalized to total STAT3. Data are mean ±SEM for N=3 independent experiments. 
***p<0.001 using a one-way ANOVA with Bonferroni post hoc test. (C) U4C cells were 
subject to a mock transfection (M) or transiently transfected with WT, V658F, or V658F 
SSAA JAK1 construct then treated with vehicle or A769662 (100 µM) for 30 min as 
indicated.. Data were analyzed as in (B); **p<0.01. 
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